Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline May 7, 2026 Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise Apr 9, 2026 Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer Feb 24, 2026 Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Jan 6, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline May 7, 2026
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise Apr 9, 2026
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer Feb 24, 2026
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Jan 6, 2026
